AP2005003363A0 - 2-Aminocarbonyl-quinoline componds as platelet ad enosine diphosphate receptor antagonists. - Google Patents

2-Aminocarbonyl-quinoline componds as platelet ad enosine diphosphate receptor antagonists.

Info

Publication number
AP2005003363A0
AP2005003363A0 AP2005003363A AP2005003363A AP2005003363A0 AP 2005003363 A0 AP2005003363 A0 AP 2005003363A0 AP 2005003363 A AP2005003363 A AP 2005003363A AP 2005003363 A AP2005003363 A AP 2005003363A AP 2005003363 A0 AP2005003363 A0 AP 2005003363A0
Authority
AP
ARIPO
Prior art keywords
enosine
componds
aminocarbonyl
quinoline
platelet
Prior art date
Application number
AP2005003363A
Other languages
English (en)
Inventor
Morrissey Michael
Ping Wei Guo
Xu Wei
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AP2005003363A0 publication Critical patent/AP2005003363A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
AP2005003363A 2002-12-11 2003-12-09 2-Aminocarbonyl-quinoline componds as platelet ad enosine diphosphate receptor antagonists. AP2005003363A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43279202P 2002-12-11 2002-12-11
PCT/US2003/039079 WO2004052366A1 (en) 2002-12-11 2003-12-09 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists

Publications (1)

Publication Number Publication Date
AP2005003363A0 true AP2005003363A0 (en) 2005-09-30

Family

ID=32507994

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003363A AP2005003363A0 (en) 2002-12-11 2003-12-09 2-Aminocarbonyl-quinoline componds as platelet ad enosine diphosphate receptor antagonists.

Country Status (23)

Country Link
US (2) US7056923B2 (de)
EP (1) EP1578423B1 (de)
JP (1) JP4662777B2 (de)
KR (1) KR20050085580A (de)
CN (1) CN1747732A (de)
AP (1) AP2005003363A0 (de)
AT (1) ATE477800T1 (de)
AU (1) AU2003297763A1 (de)
BR (1) BR0317222A (de)
CA (1) CA2507657C (de)
DE (1) DE60333866D1 (de)
EA (1) EA200500899A1 (de)
EC (1) ECSP055912A (de)
ES (1) ES2348942T3 (de)
MX (1) MXPA05006302A (de)
NO (1) NO20053335L (de)
NZ (1) NZ540872A (de)
OA (1) OA12970A (de)
PL (1) PL377053A1 (de)
RS (1) RS20050450A (de)
UA (1) UA83648C2 (de)
WO (1) WO2004052366A1 (de)
ZA (1) ZA200505492B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
JP2007514647A (ja) * 2003-10-21 2007-06-07 インスパイアー ファーマシューティカルズ,インコーポレイティド テトラヒドロ−フロ[3,4−d]ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
DE102006020385A1 (de) * 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
CL2007002920A1 (es) * 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
MX2009011089A (es) * 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
AU2008266515B2 (en) 2007-06-18 2014-05-01 Sanofi Pyrrole derivatives as P2Y12 antagonists
EP2225253B1 (de) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonsäurederivate und ihre verwendung als p2y12-rezeptorantagonisten
AR071652A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
CN102304108B (zh) * 2011-06-28 2013-11-06 中国药科大学 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途
CN104151235B (zh) * 2014-08-07 2016-01-20 南阳师范学院 一种喹啉衍生物制备方法
EP3515924B1 (de) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Kristalline formen
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
CN112062687B (zh) * 2020-09-02 2023-11-21 上海信谊万象药业股份有限公司 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法
CN112920181A (zh) * 2021-01-29 2021-06-08 中国医科大学 N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US60474A (en) * 1866-12-18 Pbtee chick
GB1334705A (en) 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
AU8868991A (en) 1990-11-15 1992-06-11 Pentapharm Ag Meta-substituted phenyl alanine derivatives
JPH07509731A (ja) * 1993-02-10 1995-10-26 ペンタファルム アクチェンゲゼルシャフト トロンビン阻害剤としての置換されたフェニルアラニン誘導体のピペラジド
KR0173034B1 (ko) * 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists

Also Published As

Publication number Publication date
OA12970A (en) 2006-10-13
MXPA05006302A (es) 2005-08-29
DE60333866D1 (de) 2010-09-30
EP1578423A1 (de) 2005-09-28
ES2348942T3 (es) 2010-12-17
CA2507657C (en) 2011-05-31
WO2004052366A9 (en) 2005-06-23
NO20053335D0 (no) 2005-07-08
PL377053A1 (pl) 2006-01-23
US7084142B2 (en) 2006-08-01
NO20053335L (no) 2005-09-07
BR0317222A (pt) 2005-11-01
ATE477800T1 (de) 2010-09-15
US7056923B2 (en) 2006-06-06
EA200500899A1 (ru) 2006-02-24
JP2006511519A (ja) 2006-04-06
CA2507657A1 (en) 2004-06-24
US20040138229A1 (en) 2004-07-15
US20060122188A1 (en) 2006-06-08
ZA200505492B (en) 2006-03-29
ECSP055912A (es) 2005-11-22
EP1578423B1 (de) 2010-08-18
CN1747732A (zh) 2006-03-15
RS20050450A (sr) 2007-08-03
AU2003297763A1 (en) 2004-06-30
KR20050085580A (ko) 2005-08-29
WO2004052366A1 (en) 2004-06-24
JP4662777B2 (ja) 2011-03-30
NZ540872A (en) 2007-08-31
UA83648C2 (ru) 2008-08-11

Similar Documents

Publication Publication Date Title
AP2005003363A0 (en) 2-Aminocarbonyl-quinoline componds as platelet ad enosine diphosphate receptor antagonists.
IL174538A0 (en) Thrombin receptor antagonists
IL165841A0 (en) Mchir antagonists
IL182090A0 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
AU2003259267A8 (en) Substituted aminopyrimidines as neurokinin antagonists
EP1553075A4 (de) Lpa-rezeptor-antagonisten
AP2006003566A0 (en) Muscarinic Acetycholine receptor antagonists.
IL164585A0 (en) Tricyclic thrombin receptor antagonists
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
AU2003268304A8 (en) Toolholder
IS7697A (is) Pýrimídýlsúlfónamíðafleiður sem miðlar flakkboðaviðtaka
IL175084A0 (en) Antagonists of the bradykinin b1 receptor
IL163939A0 (en) Nk1 antagonists
PL378753A1 (pl) Antagoniści receptora CCR-3
IL165727A0 (en) Chemokine antagonists
GB0226227D0 (en) Receptors
EP1636230A4 (de) A1-adenosinrezeptorantagonisten
IL173337A0 (en) Receptor
GB0302094D0 (en) EP4 receptor antagonists
GB0215389D0 (en) Receptor
GB0223399D0 (en) Receptors
HK1083750A (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
GB0321998D0 (en) Receptor
GB0214443D0 (en) Tuft
HK1086837A (en) Thrombin receptor antagonists